Aurobindo Pharma Sees Significant Open Interest Surge Amid Bullish Derivatives Activity

Open Interest and Volume Dynamics

On 30 Jan 2026, Aurobindo Pharma’s open interest (OI) in derivatives rose sharply by 7,256 contracts, a 16.4% increase from the previous day’s 44,253 to 51,509. This notable expansion in OI accompanied a robust volume of 49,489 contracts, underscoring heightened trading activity. The futures segment alone accounted for a value of approximately ₹79,389 lakhs, while options contributed a staggering ₹25,662 crores, culminating in a total derivatives value of ₹86,863 lakhs. Such figures reflect a strong interest in both futures and options, suggesting that traders are positioning aggressively ahead of anticipated price movements.

Price Performance and Market Context

The underlying stock price of Aurobindo Pharma closed at ₹1,178, marking a day gain of 2.31%. The stock opened with a gap-up of 3.42% and touched an intraday high of ₹1,214.7, a 5.57% rise, outperforming the Pharmaceuticals & Biotechnology sector by 2% and the Sensex, which declined by 0.58%. Over the past three consecutive sessions, the stock has delivered a cumulative return of 4.27%, signalling sustained buying interest. The price currently trades above its 5-day, 20-day, 100-day, and 200-day moving averages, though it remains slightly below the 50-day average, indicating a mixed but generally bullish technical setup.

Investor Participation and Liquidity

Despite the price rally, delivery volumes on 29 Jan 2026 stood at 2.82 lakh shares, marginally down by 0.95% compared to the five-day average, suggesting a slight dip in long-term investor participation. However, liquidity remains adequate, with the stock’s average traded value supporting trade sizes up to ₹1.38 crore comfortably, facilitating smooth execution for institutional and retail participants alike.

Market Positioning and Directional Bets

The surge in open interest alongside rising volumes and price gains points to a bullish sentiment among derivatives traders. The increase in futures value to nearly ₹79,389 lakhs suggests that participants are taking long positions, anticipating further upside in the stock price. Concurrently, the substantial options value exceeding ₹25,662 crores indicates active hedging and speculative strategies, with call options likely dominating given the positive price momentum.

Such positioning is consistent with the stock’s recent upgrade in mojo grade from Buy to Hold on 1 Dec 2025, reflecting a more cautious but still constructive outlook. The mojo score of 55.0 and a market cap grade of 2 (mid-cap) highlight moderate quality and growth potential, making Aurobindo Pharma an attractive candidate for selective accumulation rather than aggressive buying.

Comparative Sector and Index Analysis

While Aurobindo Pharma outperformed its sector by 2% and the Sensex declined by 0.58% on the day, the broader Pharmaceuticals & Biotechnology sector showed muted gains of 0.46%. This relative strength underscores the stock’s leadership within its industry group, driven by favourable fundamentals and positive market sentiment. Investors should note that the stock’s recent three-day rally and gap-up opening reflect a shift in momentum that could attract further interest if sustained.

Technical Indicators and Moving Averages

The stock’s position above key short- and long-term moving averages, except the 50-day average, suggests a consolidation phase with potential for breakout. The 50-day moving average often acts as a resistance level; a decisive move above it could trigger additional buying. Conversely, failure to breach this level may lead to profit-taking or sideways trading. Traders should monitor volume trends and open interest changes closely to gauge the strength of the ongoing move.

Outlook and Investor Considerations

Given the current derivatives activity and price action, Aurobindo Pharma appears poised for cautious optimism. The increase in open interest and volume signals that market participants are positioning for a potential upward move, supported by strong sector fundamentals and the company’s mid-cap status with a sizeable market capitalisation of ₹69,987 crore.

However, the downgrade in mojo grade from Buy to Hold suggests that investors should remain vigilant for any signs of volatility or profit-booking. The slight decline in delivery volumes indicates that long-term holders may be less active, possibly awaiting clearer trend confirmation. As such, traders might consider a balanced approach, leveraging technical signals and derivatives data to time entries and exits effectively.

Summary

Aurobindo Pharma’s derivatives market has demonstrated a marked increase in open interest and trading volumes, reflecting renewed bullish sentiment. The stock’s outperformance relative to its sector and the Sensex, combined with positive technical indicators, supports a constructive near-term outlook. Nonetheless, the recent mojo grade adjustment and mixed investor participation counsel prudence. Monitoring open interest trends and price action will be crucial for investors seeking to capitalise on this momentum while managing risk.

Unlock special upgrade rates for a limited period. Start Saving Now →